Link to Otsuka Global

OPDC  OMML

 
Contact us | Search Site | Site Map
This is a spacer image
Products
Pharmaceutical Products
Medical Devices
Pipeline
Return Goods Policy




Font Size:
Home About OAPI Press Releases Products Neuroscience Careers OPDC OMML Contact Us Search Site Map
OAPI IV BUSULFEX
§

IV BUSULFEX1  is a conditioning agent, in combination with cyclosphosphamide, prior to allogeneic hemotopoietic stem cell transplantation (also referred to as blood or marrow transplantation or BMT) in patients with chronic myelogenous leukemia (CML).  

 

For more information on IV BUSULFEX, please visit www.ivbusulfex.com.

 
1 Please see FULL PRODUCT INFORMATION including Boxed WARNING for IV BUSULFEX.
 




* OAPI, OPDC and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd.